Premium
Interferon‐α is not elevated in idiopathic thrombotic thrombocytopenic purpura patients
Author(s) -
Watanaboonyongcharoen Phandee,
Whinna Herbert C.,
Park Yara A.
Publication year - 2014
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/jca.21322
Subject(s) - medicine , autoantibody , adamts13 , thrombotic thrombocytopenic purpura , immunology , population , autoimmune disease , platelet , cytokine , interferon , thrombocytopenic purpura , antibody , environmental health
Idiopathic thrombotic thrombocytopenic purpura (TTP) patients have ADAMTS13 deficiency, which is usually caused by ADAMTS13 autoantibodies. However, the triggering factors for the autoantibody production remain unclear. Interferon‐α (IFN‐α) is a cytokine involved with many autoimmune processes such as inducing the activation of peripheral dendritic cells and stimulating T cells and B cells. It also plays an important role in some autoimmune diseases. Elevated IFN‐α levels have been observed in some TTP patients and previous case reports have shown the occurrence of TTP after IFN‐α treatment. Thus, we hypothesized that high levels of IFN‐α would correlate with presence of ADAMTS13 autoantibodies. However, we did not observe elevated IFN‐α levels in 36 TTP patients (mean 5.29 pg/ml, standard deviation (SD) 26.56 pg/ml) compared to healthy controls (mean 0 pg/ml, SD 0 pg/ml), P = 0.59. IFN‐α levels of most patients (94%) were undetectable. Only two patients had increased IFN‐α levels and ADAMTS13 autoantibodies were detected in these two patients. Interestingly, both the patients had an underlying autoimmune disease. Although there have been cases of secondary TTP following IFN‐α treatment, no evidence supports a role of IFN‐α in the development of idiopathic TTP in our patient population. J. Clin. Apheresis 29:336–338 2014. © 2014 Wiley Periodicals, Inc.